Digital Pathway - Changing The Treatment Paradigm for LDL-C Lowering Post-MI: The Case for Early, ‘High-Intensity Lipid Lowering Therapy’ to Improve Outcomes
Patients with a recent myocardial infarction (MI) are at very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events, however, targeted LDL-C goal achievement and optimization of lipid lowering therapy (LLT) in these patients remains suboptimal. In turn, these gaps perpetuate the risk of future adverse events that patients with a recent MI will experience. Despite the intensive medical management following an MI, risk of a recurrent CV event is substantial and patients with a recent MI have significant loss of productivity the year after the event. Furthermore, this burden is more pronounced in very high-risk patients, including those with a high burden of cardiometabolic comorbidities, compared to patients who are not very-high risk.
During this activity, experts will provide guidance on the individualization of statin and non-statin therapies in this setting, as well as how to address the current inertia in order to optimize outcomes. The design of this activity ensures that these topics are presented in a format that is easy to follow, containing a mix of videos & resources, organized into different segments to facilitate learning.
This activity is part of CMHC's Lipid Management Digital Education Hub.
The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
After completing this activity, the participant should be better able to:
- Review current guideline recommendations for lipid testing, lipid targets, and lipid-lowering therapy in patients with a recent MI
- Explain the efficacy and safety of PCSK9 inhibitors in patients with a recent Ml and their implications for patient selection
- Describe individualized treatment strategies for very-high risk ASCVD patients with a recent Ml that prioritize the early initiation and intensification of treatment to optimize overall outcomes.
Christie M. Ballantyne, MD
Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Dr. Ballantyne discloses the following:
Consulting Fee (e.g., Advisory Board): Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken*, Esperion, Genetech, Gilead, Illumina, Matinas BioPharma Inc, Merck, New Amsterdam*, Novartis, Novo Nordisk, Pfizer, Regeneron, Roch Diagnostic, Sanofi-Synthelabo
Contracted Research (Principal Investigators must provide information, even if received by the institution): Grant/Research Support - All Significant (All paid to institution, not individual): Abbott-Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Novartis, Novo Nordisk, Regeneron, Roch Diagnostic
Pam R. Taub, MD, FACC, FASPC
Professor of Medicine
Director, Step Family Foundation Cardiac
Rehabilitation and Wellness Center
UC San Diego
San Diego, CA
Dr. Taub discloses the following:
Consulting Fee (e.g., Advisory Board): Applied Therapeutics, Amgen, Bayer, Boehringer-Ingelheim, Esperion therapeutics, Medtronic, Novartis, Novo-Nordisk, Sanofi
Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Epirium Bio
Salim S. Virani, MD, PhD
Associate Professor, Section of Cardiovascular Research
Director, Cardiovascular Disease Fellowship Training Program
Baylor College of Medicine
Staff Cardiologist, Michael E. DeBakey
Veterans Affairs Medical Center
Investigator, Health Policy, Quality and Informatics Program
Michael E. DeBakey Veterans Affairs Medical Center
HSR&D Center for Innovations
Dr. Virani has nothing to disclose.
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported by educational funding provided by Amgen.
JOINT PROVIDERSHIP STATEMENT
This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACIST ACCREDITATION STATEMENT
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.115 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN): 0530-9999-22-233-H01-P.
This is a knowledge-based activity.
DIETICIAN ACCREDITATION STATEMENT
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012
CDR learners may submit their program evaluation directly to the CDR.
GLOBAL CONTACT INFORMATION
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com..
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The planners and managers have the following relevant financial relationships with ineligible companies:
|Name of Planner or Manager||Reported Financial Relationship|
|Rhys Williams, MSN, FNP-C, RN||Nothing to disclose.|
|Lindsay Borvansky||Nothing to disclose.|
|Andrea Funk||Nothing to disclose.|
|Liddy Knight||Nothing to disclose.|
|Ashley Cann||Nothing to disclose.|
|Karin McAdams||Nothing to disclose.|
|Shpetim Karandrea, PhD||Nothing to disclose.|
|Neha Agarwal, PhD||Nothing to disclose.|
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
This activity is complimentary and available during the period September 23, 2022 through September 23, 2023. Participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 70% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please contact Global at 303-395-1782 or firstname.lastname@example.org.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDE
- 1.50 Participation
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.